ArticleBritish journal of cancer2008

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer.

D A Cameron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.